FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 17654 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Psychedelics for major depression-From controlled research settings into broader clinical use. PMID 40961925 · Cell Rep Med · 2025-Sep-16 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of benvitimod 1% cream for atopic dermatitis in patients aged 2 years and older: A phase III randomized clinical trial. PMID 40960153 · Chin Med J (Engl) · 2025-Sep-16 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Clinical pharmacology and therapeutic applications of talazoparib: a comprehensive review. PMID 40956449 · Cancer Chemother Pharmacol · 2025-Sep-16 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| CHOSEN: A Randomized Controlled Feasibility Trial. PMID 40932100 · J Am Heart Assoc · 2025-Sep-16 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Toripalimab Combination Therapy Without Concurrent Cisplatin for Nasopharyngeal Carcinoma: The DIAMOND Randomized Clinical Trial. PMID 40839372 · JAMA · 2025-Sep-16 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedsafety_or_economic_primary_endpoint | pending 0 Figure · 0 Panel · risk - |
| Berberine for preventing colorectal adenoma recurrence and neoplasm occurrence: 6-Year follow-up of a randomized clinical trial. PMID 40795846 · Cell Rep Med · 2025-Sep-16 The study is an oncology randomized trial with a drug intervention (berberine) and reports original results on adenoma recurrence. However, the phase is not explicitly stated as Phase III/IIIb or Phase II/III; it is an extended follow-up of a previous trial, but the original trial's phase is not specified in the record. The primary endpoint is adenoma recurrence (a categorical outcome), not a time-to-event endpoint (OS, PFS, etc.) or Kaplan-Meier/HR analysis. Therefore, it fails the 'phase3_or_definitive' and 'time_to_event' criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Doravirine/Islatravir (100/0.75 mg) Once-Daily Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide as Initial HIV-1 Treatment: 48-Week Results From a Phase 3, Randomized, Controlled, Double-Blind, Noninferiority Trial. PMID 40079835 · Clin Infect Dis · 2025-Sep-16 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Effectiveness of Electrocautery, Topical Cidofovir, and Topical Sinecatechins for the Treatment of Anal High-Grade Squamous Intraepithelial Lesions in Persons With HIV: An Open-Label, Randomized Controlled Trial. PMID 40036375 · Clin Infect Dis · 2025-Sep-16 The record is excluded because it lacks an explicit time-to-event primary/key secondary efficacy endpoint. The primary endpoint is histological resolution (binary), and while recurrence is analyzed with a log-rank test, the abstract does not provide KM estimates, medians, or HRs, so a time-to-event signal cannot be reliably established. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Impact of Setmelanotide on Metabolic Syndrome Risk in Patients With Bardet-Biedl Syndrome. PMID 39919037 · J Clin Endocrinol Metab · 2025-Sep-16 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Synergistic Effects of Psychological Resilience Training and Nutritional Support on Postoperative Recovery, Nutritional Reconstitution, Sleep Quality, and Long-Term Survival in Gastric Cancer: A Randomized Controlled Trial. PMID 40954394 · Ann Surg Oncol · 2025-Sep-15 The study is a randomized, oncology, human trial with primary time-to-event endpoints (DFS, OS) and original results. However, it does not meet the core eligibility requirement of a drug-containing intervention, as the intervention is psychological and nutritional support, not a pharmacological agent. The trial phase is also not explicitly stated as Phase III/IIIb or Phase II/III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Two-Week Course versus Conventionally Fractionated Preoperative Chemoradiotherapy Followed by Total Mesorectal Excision in Locally Advanced Rectal Cancer (Twoarc Trial): A Phase III Randomized Clinical Trial. PMID 40939157 · Ann Surg · 2025-Sep-15 The study is a Phase III randomized trial with drug intervention, but its primary endpoint is pathologic response (downstaging rate), not a time-to-event efficacy endpoint such as OS, PFS, DFS, EFS, RFS, TTP, or an analysis using Kaplan-Meier or HR. Therefore, it does not meet the inclusion criterion for a primary/key secondary time-to-event efficacy endpoint. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Durvalumab versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial. PMID 40705396 · Clin Cancer Res · 2025-Sep-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Comparing the Efficacy and Safety of Fexuprazan and Lansoprazole for the Prevention of Nonsteroidal Anti-inflammatory Drug-Induced Peptic Ulcer. PMID 40567214 · Gut Liver · 2025-Sep-15 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Comparative Efficacy of Potassium-Competitive Acid Blocker-Based Triple Therapy with Tegoprazan versus Vonoprazan for Helicobacter pylori Eradication: A Randomized, Double-Blind, Active-Controlled Pilot Study. PMID 40462641 · Gut Liver · 2025-Sep-15 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| The effect of adjunctive cariprazine on symptoms of anhedonia in patients with major depressive disorder. PMID 40339720 · J Affect Disord · 2025-Sep-15 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Flap sparing in postoperative radiotherapy versus standard flap-agnostic radiotherapy of oral cavity cancers (OPTIFLAP): protocol for a de-escalation, randomised, non-inferiority, phase III trial. PMID 40953868 · BMJ Open · 2025-Sep-14 方案论文未报告临床试验结果。 |
H
S
B
|
严格 v3 独有 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Trajectories of Recovery after Intravenous propofol versus inhaled VolatilE anaesthesia (THRIVE) randomised controlled trial in the USA: A protocol. PMID 40953862 · BMJ Open · 2025-Sep-14 The record is a protocol for a randomised trial comparing anaesthetic techniques (propofol vs. volatile anaesthesia) in patients undergoing non-cardiac surgery. It is not an oncology trial, the primary endpoint is a patient-reported recovery score (QOR-15), and it reports no results. Therefore, it fails the core eligibility criteria for inclusion in the oncology Kaplan-Meier digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Immunogenicity and Safety of a Live Attenuated Varicella Vaccine in Healthy Children Aged 12 to 15 Months: A Phase III, Randomized, Double-Blind, Active-Controlled Clinical Trial. PMID 41012176 · Vaccines (Basel) · 2025-Sep-13 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Safety and Immunogenicity of Single-Dose of Adsorbed Tetanus Vaccine in Adults Aged 18-44 Years: Randomized, Double-Blind, Positive-Controlled Phase I/III Clinical Trial. PMID 41012175 · Vaccines (Basel) · 2025-Sep-13 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Analysis of treatment-free survival of patients with advanced melanoma receiving nivolumab as monotherapy or in combination with relatlimab in RELATIVITY-047. PMID 40940136 · J Immunother Cancer · 2025-Sep-12 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Long-Term Survival on Extent of Lymphadenectomy for Right-Sided Colon Cancer: Five-Year Follow-up Results of a Randomized Controlled Trial (RELARC Trial). PMID 40938728 · Ann Surg · 2025-Sep-12 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of low- versus high-dose-LSD-assisted therapy in patients with major depression: A randomized trial. PMID 40482648 · Med · 2025-Sep-12 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy of natalizumab in secondary progressive multiple sclerosis: analysis of two phase III trials. PMID 40050011 · J Neurol Neurosurg Psychiatry · 2025-Sep-12 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Long-term maintenance of mycophenolate mofetil in anti-NMDA receptor encephalitis (LEARN): a multicentre, open-label, blinded-endpoint, randomised controlled trial. PMID 40015729 · J Neurol Neurosurg Psychiatry · 2025-Sep-12 未发现恶性肿瘤人群证据。 |
B
|
仅广召回影子组 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Endovascular management of intracranial carotid blowout syndrome in patients with head and neck cancer. PMID 39237154 · J Neurointerv Surg · 2025-Sep-12 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial. PMID 40935571 · BMJ · 2025-Sep-11 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 |
H
L
B
|
旧查询独有 | excludedsafety_or_economic_primary_endpoint | pending 0 Figure · 0 Panel · risk - |
| Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy. PMID 40888717 · N Engl J Med · 2025-Sep-11 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy. PMID 40888697 · N Engl J Med · 2025-Sep-11 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Protocol: Faecal microbiota transfer in liver cancer to overcome resistance to atezolizumab/bevacizumab - a multicentre, randomised, placebo-controlled, double-blind phase II trial (the FLORA trial). PMID 40930564 · BMJ Open · 2025-Sep-09 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Using American Sign Language-Fluent Community Health Navigators to Advance Cancer Screening Adherence through Videoconferencing With Deaf, Deafblind, and Hard of Hearing Adults: Protocol for a Randomized Controlled Trial. PMID 40925603 · JMIR Res Protoc · 2025-Sep-09 The record is a protocol for a randomized controlled trial testing a non-drug intervention (ASL-fluent community health navigator) for cancer screening adherence, with primary/secondary outcomes being screening completion, communication, and knowledge. It does not present results from a Phase III/IIIb or Phase II/III randomized trial of a drug-containing intervention, and no time-to-event efficacy endpoint is specified. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| DigiNet: Optimizing personalized care for patients with stage IV non-small cell lung cancer (NSCLC) through a digitally connected provider network-analysis plan of a prospective multicenter cohort trial. PMID 40924208 · J Cancer Res Clin Oncol · 2025-Sep-09 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-small cell lung cancer: Patient satisfaction and resource utilization results from the PALOMA-3 study. PMID 40730077 · Eur J Cancer · 2025-Sep-09 The record is from a relevant phase 3 oncology RCT with a drug intervention, but this specific publication reports secondary, non-efficacy outcomes (patient satisfaction, resource utilization) and does not present the formal results for a primary or key secondary time-to-event efficacy endpoint like OS or PFS. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Impact of trifluridine/tipiracil plus bevacizumab on tumor shrinkage and depth of response in refractory metastatic colorectal cancer: analysis of the SUNLIGHT trial. PMID 40694985 · Eur J Cancer · 2025-Sep-09 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Patient-related prognostic factors in older adults with head and neck cancer: The EGeSOR clinical trial. PMID 40684734 · Eur J Cancer · 2025-Sep-09 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Response to letter to the editor on "Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76K trial". PMID 40680468 · Eur J Cancer · 2025-Sep-09 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Impact of concomitant medication on recurrence, survival and tolerability of chemotherapy in early colon cancer patients - A post-hoc analysis of the PETACC 8 trial. PMID 40680466 · Eur J Cancer · 2025-Sep-09 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Letter Re: Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76 K trial. PMID 40680465 · Eur J Cancer · 2025-Sep-09 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| The association between pretreatment emotional distress and response to tumor-infiltrating lymphocyte therapy in advanced melanoma. PMID 40674829 · Eur J Cancer · 2025-Sep-09 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Randomized clinical efficacy and safety study of peltopepimut-S plus cemiplimab compared to cemiplimab alone in patients with recurrent/metastatic HPV16-positive head and neck cancer. PMID 40921630 · J Immunother Cancer · 2025-Sep-08 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of upadacitinib maintenance therapy in patients with moderately to severely active Crohn's disease: 2-year results from the U-ENDURE Long-Term Extension study. PMID 40704669 · J Crohns Colitis · 2025-Sep-07 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Perampanel, Brivaracetam, Cenobamate, Stiripentol, and Ganaxolone in Lennox-Gastaut Syndrome: A Comprehensive Narrative Review. PMID 40944069 · J Clin Med · 2025-Sep-06 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Impact of Intraoperative Lidocaine During Oncologic Lung Resection on Long-Term Outcomes in Primary Lung Cancer: A Post Hoc Analysis of a Randomized Controlled Trial. PMID 40941021 · Cancers (Basel) · 2025-Sep-06 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Effective nutritional intervention improves the health-related quality of life (HRQL) of undernourished children with cancer: results of a randomized, controlled phase 3 trial. PMID 40913629 · Support Care Cancer · 2025-Sep-06 The study is an oncology Phase III randomized controlled trial in humans with a primary result report, but it is excluded because the intervention is non-drug (nutritional) and the endpoint is not time-to-event efficacy. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Choosing the best first-line therapy for extensive-stage small-cell lung cancer: anti-PD-1 or anti-PD-L1 inhibitors? PMID 40922293 · Medicine (Baltimore) · 2025-Sep-05 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| A phase II trial of hepatic ablation of metastases to modulate and enhance immunotherapy response in non-small cell lung cancer (HAMMER-NSCLC). PMID 40898159 · BMC Cancer · 2025-Sep-02 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| CARBOMETASPINE: protocol for a multicenter, prospective, randomized controlled trial of carbonfiber spinal fixation in metastatic disease. PMID 40898139 · BMC Cancer · 2025-Sep-02 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Effect of PCSK9 Inhibition With Alirocumab in Patients With Probable Familial Hypercholesterolemia or Type III Hyperlipoproteinemia: Results From the ODYSSEY OUTCOMES Trial. PMID 40847481 · J Am Heart Assoc · 2025-Sep-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Alteplase for Acute Ischemic Stroke at 4.5 to 24 Hours: The HOPE Randomized Clinical Trial. PMID 40773205 · JAMA · 2025-Sep-02 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Physical activity and mobility disability in older adult cancer survivors. PMID 40930715 · JNCI Cancer Spectr · 2025-Sep-01 The trial is a randomized clinical trial in older adults, but the intervention is a physical activity program, not a drug. While it includes cancer survivors as a subgroup, it is not a trial of a cancer treatment. Therefore, it does not meet the oncology drug intervention criterion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Impact of temporary atezolizumab and bevacizumab interruption on survival in advanced HCC: an IMbrave150 analysis. PMID 40891895 · Oncologist · 2025-Sep-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |